|


Clinical aspects of TB
Clinical
presentation
HIV
and tuberculosis :.
HIV infection
is a risk factor for the development of tuberculosis. HIV infection
results in a progressive decline in immune function, characterised
by a loss of CD4+ T lymphocytes eventually resulting in the patient
developing one or more opportunistic diseases. Tuberculosis is one
of those opportunistic diseases and pulmonary tuberculosis has been
included as an AIDS defining illness in the AIDS case-definition
used in the United States. In Hong Kong before July 1995, only the
extrapulmonary form of tuberculosis was included as the primary
AIDS-defining illness. From July 1995 onwards, the pulmonary or
cervical lymph node involvement of TB have also been included as
primary AIDS-defining illnesses in Hong Kong if the CD4 count is
less than 200/ml.
A person with
HIV infection may develop tuberculosis as a result of:
a) reactivation
of previous infection. This is likely to be the commonest mechanism
of disease development in countries where most adults have been
infected.
b) progression from recent
infection.
c) re-infection. Due to immuno-suppression,
patients with HIV infection may not be resistant to re-infection.
The clinical
presentation of HIV-associated tuberculosis is dependent on the
degree of underlying immuno-deficiency. Tuberculosis often occurs
relatively early in the course of immune deficiency. In the earliest
stages of HIV disease, the presentation is similar to that of patients
without HIV infection. As patients become more immuno-suppressed,
the presentation becomes increasingly atypical and disseminated.
Overall, HIV positive patients are more likely to have extra-pulmonary
disease than HIV negative patients.
There are specific
problems in:
a) diagnosis
- increased frequency of false negative tuberculin tests, sputum
smear-negative disease, atypical radiological manifestations.
Also increased risk of infection with non-tuberculous mycobacteria
(eg M Avium, M Bovis etc.)
b) treatment - increased rates
of side-effects of drugs, drug interactions, and increased mortality.
|